EAU 2021: PURE-02: An Open-Label, Single-Arm, Feasibility Study of Neoadjuvant Pembrolizumab Before Radical Nephroureterectomy (Rnu) in Patients With High-Risk, Upper-Tract Urothelial Carcinoma (UTUC)

(UroToday.com) In this abstract at the 2021 European Association of Urology (EAU) annual meeting, Dr. Andrea Necchi presents the preliminary, feasibility results of the PURE-02 study, which assesses the use of pembrolizumab before radical nephroureterectomy in patients with high-risk Upper tract urothelial cancer (UTUC).